We also observed increased levels of CCL5 and CCL3, expressed in NK cells, that interact with the CD191 receptor (CCR1), and whose inhibition potentially suppresses immune hyperactivation in critical COVID-19 patients [69]. The gene discussed is CCR1; the disease is COVID-19.